Ecron Acunova launches direct operation in Russia

By ANI
Thursday, November 19, 2009

BANGALORE - Ecron Acunova, a full-service clinical research organization (CRO), with offices across Europe, in India and the US, has strengthened its Eastern European presence further by opening a new office in Moscow, Russia in October 2009.

Galyna Andriyko has been named as General Manager. She will lead the development of the Russian office operations.

Dr. Antal K. Hajos, Managing Director and CEO, Ecron Acunova, Europe said: “This is another key step for Ecron Acunova in creating a unique platform for clients to fully benefit from the strengths of global reach with local expertise. Russia has substantial unexplored capabilities.

With its 141 million population and well recognized experience in clinical trials, Russia allows high recruitment rates, low drop-out rates and high quality data, to be obtained by dedicated medical professionals. With Mrs Andriyko’s expertise, we look forward to strengthening clinical trials in this region”.

Andriyko has successfully set up operations in Ukraine, delivering high quality results at competitive costs. The clinical team will be headed by Dr. Vlad Linievych, a physician, who has over 13 years of experience in industry. Ecron Acunova has been active in Russia for several years via collaborations and enjoys sound contacts to clinical trial sites.

Ecron Acunova has 23 years of clinical expertise. Across Europe alone, Ecron Acunova covers 14 countries. In CEE Ecron Acunova has own offices since 2004 in the Czech Republic (Prague), Poland (Warsaw) and Ukraine (Kyiv).

Through the new office in Russia, Ecron Acunova expands its current success in delivering client focused services. With its strong presence and local expertise, the company manages the most challenging time, costs and quality demands of its clients in the key clinical trial markets of the region. (ANI)

Filed under: Business

Tags:
YOUR VIEW POINT
NAME : (REQUIRED)
MAIL : (REQUIRED)
will not be displayed
WEBSITE : (OPTIONAL)
YOUR
COMMENT :